The composite primary efficacy endpoint was percentage of patients whose haematological variables and organ volumes remained stable for 12 months ( ie , haemoglobin decrease not more than 15 g/L , platelet count decrease not more than 25 % , spleen volume increase not more than 25 % , and liver volume increase not more than 20 % , in multiples of normal from baseline ) .